{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T19:26:44Z","timestamp":1782156404029,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,30]]},"DOI":"10.7759\/cureus.17551","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T10:34:26Z","timestamp":1630319666000},"source":"Crossref","is-referenced-by-count":1,"title":["Raynaud\u2019s Secondary to Granulomatosis With Polyangiitis"],"prefix":"10.7759","author":[{"given":"Sai Swarupa","family":"Vulasala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohana","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmal  K","family":"Onteddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneesh","family":"Mannem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Mukkera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0754","article-title":"Raynaud's phenomenon","volume":"20","author":"Haque A","year":"2020","unstructured":"Haque A, Hughes M. Raynaud's phenomenon. Clin Med (Lond). 2020, 20:580-7. 10.7861\/clinmed.2020-0754","journal-title":"Clin Med (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2421760","article-title":"A rare case of digital ischemia and gangrene in ANCA-associated vasculitis with review of the literature","volume":"2017","author":"Lau RA","year":"2017","unstructured":"Lau RA, Bains R, Suraweera D, Ma J, Heinze ER, Wong AL, Clements PJ. A rare case of digital ischemia and gangrene in ANCA-associated vasculitis with review of the literature. Case Rep Rheumatol. 2017, 2017:2421760. 10.1155\/2017\/2421760","journal-title":"Case Rep Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04745-5","article-title":"Raynaud's phenomenon-an update on diagnosis, classification and management","volume":"38","author":"Pauling JD","year":"2019","unstructured":"Pauling JD, Hughes M, Pope JE. Raynaud's phenomenon-an update on diagnosis, classification and management. Clin Rheumatol. 2019, 38:3317-30. 10.1007\/s10067-019-04745-5","journal-title":"Clin Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-010-0065-x","article-title":"Management of Raynaud's phenomenon in the patient with connective tissue disease","volume":"12","author":"Chatterjee S","year":"2010","unstructured":"Chatterjee S. Management of Raynaud's phenomenon in the patient with connective tissue disease. Curr Treat Options Cardiovasc Med. 2010, 12:185-204. 10.1007\/s11936-010-0065-x","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"ref5","article-title":"Granulomatosis with Polyangiitis","author":"Garlapati P","year":"2021","unstructured":"Garlapati P, Qurie A. Granulomatosis with Polyangiitis. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2021."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.028","article-title":"Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis)","volume":"48","author":"Lutalo PM","year":"2014","unstructured":"Lutalo PM, D'Cruz DP. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis). J Autoimmun. 2014, 48:94-8. 10.1016\/j.jaut.2014.01.028","journal-title":"J Autoimmun"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0394632015617063","article-title":"Clinic manifestations in granulomatosis with polyangiitis","volume":"29","author":"Greco A","year":"2016","unstructured":"Greco A, Marinelli C, Fusconi M, et al.. Clinic manifestations in granulomatosis with polyangiitis. Int J Immunopathol Pharmacol. 2016, 29:151-9. 10.1177\/0394632015617063","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2018.1503920","article-title":"Clinical manifestations of granulomatosis with polyangiitis: key considerations and major features","volume":"130","author":"Grygiel-G\u00f3rniak B","year":"2018","unstructured":"Grygiel-G\u00f3rniak B, Limphaibool N, Perkowska K, Puszczewicz M. Clinical manifestations of granulomatosis with polyangiitis: key considerations and major features. Postgrad Med. 2018, 130:581-96. 10.1080\/00325481.2018.1503920","journal-title":"Postgrad Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X17740074","article-title":"Evidence-based management of Raynaud's phenomenon","volume":"9","author":"Herrick AL","year":"2017","unstructured":"Herrick AL. Evidence-based management of Raynaud's phenomenon. Ther Adv Musculoskelet Dis. 2017, 9:317-29. 10.1177\/1759720X17740074","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2011.01.022","article-title":"Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review","volume":"92","author":"Huisstede BM","year":"2011","unstructured":"Huisstede BM, Hoogvliet P, Paulis WD, van Middelkoop M, Hausman M, Coert JH, Koes BW. Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review. Arch Phys Med Rehabil. 2011, 92:1166-80. 10.1016\/j.apmr.2011.01.022","journal-title":"Arch Phys Med Rehabil"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3241-1","article-title":"Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review","volume":"35","author":"Garc\u00eda de la Pe\u00f1a Lefebvre P","year":"2015","unstructured":"Garc\u00eda de la Pe\u00f1a Lefebvre P, Nishishinya MB, Pereda CA, et al.. Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. Rheumatol Int. 2015, 35:1447-59. 10.1007\/s00296-015-3241-1","journal-title":"Rheumatol Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit M","year":"2013","unstructured":"Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013, 72:1696-9. 10.1136\/annrheumdis-2012-202836","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy PD","year":"2010","unstructured":"Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, Agarwal V. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010, 49:2420-8. 10.1093\/rheumatology\/keq291","journal-title":"Rheumatology (Oxford)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0789-z","article-title":"Effects of bosentan on the skin lesions: an observational study from a single center in Japan","volume":"29","author":"Funauchi M","year":"2009","unstructured":"Funauchi M, Kishimoto K, Shimazu H, Nagare Y, Hino S, Yano T, Kinoshita K. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatol Int. 2009, 29:769-75. 10.1007\/s00296-008-0789-z","journal-title":"Rheumatol Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016660324","article-title":"Evidence for the use of epoprostenol to treat Raynaud's phenomenon with or without digital ulcers","volume":"50","author":"Cruz JE","year":"2016","unstructured":"Cruz JE, Ward A, Anthony S, Chang S, Bae HB, Hermes-DeSantis ER. Evidence for the use of epoprostenol to treat Raynaud's phenomenon with or without digital ulcers. Ann Pharmacother. 2016, 50:1060-7. 10.1177\/1060028016660324","journal-title":"Ann Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.15008","article-title":"Recent advances in the workup and management of Raynaud phenomenon","volume":"129","author":"Lis-\u015awi\u0119ty A","year":"2019","unstructured":"Lis-\u015awi\u0119ty A. Recent advances in the workup and management of Raynaud phenomenon. Pol Arch Intern Med. 2019, 129:798-808. 10.20452\/pamw.15008","journal-title":"Pol Arch Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.7934","article-title":"Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon","volume":"4","author":"Breen ID","year":"2021","unstructured":"Breen ID, Brumfiel CM, Patel MH, et al.. Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open. 2021, 4:e217934. 10.1001\/jamanetworkopen.2021.7934","journal-title":"JAMA Netw Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0698-1","article-title":"Riociguat for the treatment of Raynaud's phenomenon: a single-dose, double-blind, randomized, placebo-controlled cross-over pilot study (DIGIT)","volume":"38","author":"Huntgeburth M","year":"2018","unstructured":"Huntgeburth M, Kie\u00dfling J, Weimann G, Wilberg V, Saleh S, Hunzelmann N, Rosenkranz S. Riociguat for the treatment of Raynaud's phenomenon: a single-dose, double-blind, randomized, placebo-controlled cross-over pilot study (DIGIT). Clin Drug Investig. 2018, 38:1061-9. 10.1007\/s40261-018-0698-1","journal-title":"Clin Drug Investig"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00293","article-title":"Aminaphtone efficacy in primary and secondary Raynaud's phenomenon: a feasibility study","volume":"10","author":"Ruaro B","year":"2019","unstructured":"Ruaro B, Pizzorni C, Paolino S, Alessandri E, Sulli A. Aminaphtone efficacy in primary and secondary Raynaud's phenomenon: a feasibility study. Front Pharmacol. 2019, 10:293. 10.3389\/fphar.2019.00293","journal-title":"Front Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/art.24351","article-title":"MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial","volume":"60","author":"Chung L","year":"2009","unstructured":"Chung L, Shapiro L, Fiorentino D, et al.. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009, 60:870-7. 10.1002\/art.24351","journal-title":"Arthritis Rheum"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/68637-raynauds-secondary-to-granulomatosis-with-polyangiitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:43Z","timestamp":1707507283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/68637-raynauds-secondary-to-granulomatosis-with-polyangiitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.17551","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,30]]}}}